Company Performance Metrics
Andersen Pharmaceutical engages in pharmaceutical R&D, production, and sales. Its research project "National Class 1.1 Anti-tumor Chemical New Drug Taxideptide" has been supported by the Ministry of Science and Technology and the National Health and Family Planning Commission's "Major New Drug Creation" National Major
Project (Project No.: 2015ZX09101002), and was approved by the Standing Committee of the 11th National People's Congress. Chairman Huisang Guowei identified it as one of the two innovative drugs to be developed during the country's 13th Five-Year Plan period. In the 4th China Innovation and Entrepreneurship Competition, Anderson Pharmaceuticals stood out among more than 700 enterprises in the province, won first place in the Anhui competition area, and was shortlisted for the top 14 biopharmaceutical national industry finals, representing a rising star in domestic innovative drug research and development.
The company was founded in 2009 and is located in the Innovation Industrial Park of Hefei High-tech Zone.
